Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T17:36:50.725Z.
Calculation as of: 2026-10-06T17:36:50.725Z.
Quote observation: 2026-10-06T17:35:15.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 48f0cd224d3c7dd52ecd2cde696dbbeed4cc913852df97ed5052446ca25b90ee
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$76.37M
Price/OCF Ratio
3.48
TTM Avg
3.93
3Y Avg
19.17
5Y Avg
19.17
Market Cap
$78.07M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$78.31M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$79.96M
Price/OCF Ratio
N/A
TTM Avg
786.57
3Y Avg
786.57
5Y Avg
786.57
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Hyperfine, Inc. (HYPR) | $76.64M | N/A | N/A | N/A | N/A |
| SkinHealth Systems Inc. (SKIN)vs › | $76.37M | 3.48 | 3.93 | 19.17 | 19.17 |
| Pulmonx Corporation (LUNG)vs › | $77.08M | N/A | N/A | N/A | N/A |
| Outset Medical, Inc. (OM)vs › | $75.35M | N/A | N/A | N/A | N/A |
| Sera Prognostics, Inc. (SERA)vs › | $77.53M | N/A | N/A | N/A | N/A |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $78.07M | N/A | N/A | N/A | N/A |
| Neonc Technologies Holdings, Inc. (NTHI)vs › | $78.31M | N/A | N/A | N/A | N/A |
| Citius Oncology, Inc. (CTOR)vs › | $79.96M | N/A | 786.57 | 786.57 | 786.57 |
| Nutriband Inc. (NTRB)vs › | $80.11M | N/A | N/A | N/A | N/A |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $80.90M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
